Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma

Rha, S. Y., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J-P., Weber, P. E. Yanez, Wyrwicz, L. S., Shen, L., Ostapenko, Y. V., Bilici, M., Chung, H. C., Shitara, K., Mahave, M., van Cutsem, E., Tabernero, J., Xu, L., Sharan, K. P., Bhagia, P., Janjigian, Y. Y.